Intuitive Surgical posted 19% Q2 2026 revenue growth, driven by a larger da Vinci installed base and a recurring revenue mix that reached 85% of quarterly sales. The stock still earns only a Hold as a premium valuation limits upside despite strong operating momentum.
Investment thesis: Intuitive Surgical (ISRG) combines 19% Q2 2026 revenue growth, a 12% expansion in the da Vinci installed base, and a recurring revenue engine that generated $2.47 billion, or 85% of quarterly revenue. The business has the financial strength and clinical ecosystem to compound over a medium-term horizon, but a 43.0x trailing P/E and 36.9x forward P/E leave less room for execution errors. That combination supports a Hold recommendation for moderate-risk investors.
The operating case remains strong. Q2 2026 revenue reached $2.89 billion, GAAP EPS was $2.29, worldwide procedures increased 16%, da Vinci procedures rose 15%, and ION procedures advanced 36%. Management maintained 2026 da Vinci procedure-growth guidance of 13.5% to 15.5%, with the expected result closer to the midpoint.
The valuation case is more restrained. ISRG generated $2.49 billion of 2025 free cash flow, but the reported FCF yield is only 2.7%. Analyst estimates point to $13.27 billion of revenue and $12.08 of EPS in 2027, rising to $18.49 billion of revenue and $17.00 of EPS in 2030. That growth can support a premium, though the current multiple already prices in sustained expansion.
Intuitive Surgical (ISRG) develops robotic platforms for minimally invasive care. Its core da Vinci system supports robotic-assisted surgery, while the Ion platform focuses on robotic bronchoscopy and lung biopsy procedures. The company also sells proprietary instruments and accessories, provides system maintenance and training, and offers digital tools such as telepresence, simulation, and AI-driven case insights.
Founded in 1995 and headquartered in Sunnyvale, California, ISRG had 17,021 employees in the supplied corporate profile. The company sells through direct commercial organizations, including capital and clinical sales teams, across the United States and major international markets. That commercial structure supports system placement, surgeon training, service delivery, and procedure adoption in one operating model.
The economic model resembles a razor-and-blade system. A hospital acquires or leases a robotic platform, then purchases instruments, accessories, and service as procedures increase. In 2025, ISRG generated $10.06 billion of revenue, $2.86 billion of net income, and $3.03 billion of operating cash flow. The installed base therefore matters as much as the next system sale.
ISRG reports its business through Systems, Instruments and Accessories, and Services. Instruments and Accessories generated $6.02 billion in 2025, representing 59.8% of revenue. Systems contributed $2.47 billion, or 24.6%, while Services produced $1.57 billion, or 15.6%.
The mix shifted toward recurring revenue in Q2 2026. Instruments and Accessories revenue rose 18% to $1.73 billion, Services revenue increased 21% to $472 million, and Systems revenue grew 19% to $685 million. Recurring revenue of $2.47 billion grew 19% and accounted for 85% of total quarterly revenue.
Instruments and Accessories are the financial center of the model because each procedure creates a consumable revenue opportunity. Revenue per da Vinci procedure increased to approximately $1,830 in Q2 2026 from $1,800 a year earlier, helped by the mix of da Vinci 5 and SP procedures. The planned extended-use program for a subset of ENDORIST instruments is designed to lower customer cost per use in high-volume benign procedures, which could support adoption while reducing revenue per procedure for the affected products.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Da Vinci remains the flagship platform. As of June 30, 2026, the da Vinci installed base reached 11,710 systems worldwide, including 6,615 in the United States, 2,325 in Europe, 2,111 in Asia, and 659 in the rest of the world. Q2 placements totaled 468 systems, up 18% from 395 a year earlier.
Da Vinci 5 drove a meaningful part of the capital cycle. Of the 468 Q2 da Vinci placements, 246 were da Vinci 5 systems, including 114 dual-console systems. The da Vinci 5 installed base exceeded 1,700 systems, and more than 15,000 surgeons had used the platform since launch. Its higher system price and 11% higher utilization than Xi, as shown in the investor presentation, support both system revenue and future consumable demand.
Utilization provides the bridge between installed systems and recurring revenue. Q2 da Vinci utilization increased 3%, while the da Vinci installed base increased 12%. More than 13 million procedures have been completed on da Vinci Xi globally, giving hospitals a long operating history with the platform and giving ISRG a large base for training, service, and product development.
ISRG's competitive advantage rests on the combination of hardware, software, training, clinical evidence, and service. In Q2, the company rolled out the first phase of more than 100 planned da Vinci 5 updates focused on telepresence, simulation-based training, and care-team workflow. Multiple related innovations have been submitted for FDA 510(k) clearance.
The SP platform broadens the product range. SP procedures increased 61% in Q2, and the global SP installed base reached 445 systems after 38 placements. Extended-range instruments, custom remote-center software, Reach Assist software, and the SP stapler are expanding the platform's use in colorectal and thoracic procedures. In the United States, the SP stapler was used in nearly 60% of eligible cases in Q2, up from just under 40% in the prior quarter.
ION adds a second growth vector. ION procedures rose 36% to 48,000 in Q2 and exceeded 400,000 cumulatively. The installed base increased 21%, ION utilization rose 11%, and systems have been installed in 12 countries outside the United States. ROSE, EBUS, and a next-generation flexible robotic endoscope for gastrointestinal use extend the development pipeline beyond the current lung-focused platform.
Clinical evidence also supports the platform. A retrospective appendectomy study covering 1,430 patients found a 0% conversion-to-open rate for the robotic cohort versus 3.2% for laparoscopy, while the adjusted risk of any complication was 66% lower for the robotic approach. A separate nephrectomy cohort found that 63% of patients using force feedback achieved bowel-function recovery within one day, compared with 28% without force feedback.
Operational execution remained strong in Q2 2026. ISRG added 215 employees during the quarter, with about half joining manufacturing. Non-GAAP gross margin was 70.0%, or 68.7% excluding a $36 million pretax benefit from refunds of previously paid IEEPA tariffs. Product cost reductions and fixed-overhead leverage helped offset higher freight and semiconductor-memory costs.
Management's 2026 outlook calls for non-GAAP gross margin of 68.0% to 69.0%, including an estimated 1.0% of revenue from tariffs, and operating-expense growth of 11% to 13%. R&D is growing faster than SG&A as ISRG funds new disease-state programs, software, robotics, imaging, artificial intelligence, and advanced materials.
The 2025 10-K identifies meaningful international and manufacturing exposure. ISRG produces significant instruments and accessories in Mexico and endoscopes in Germany. The company also states that 24% of 2025 revenue was denominated in foreign currencies. The extended-use instrument program and the XiR configuration show management using product architecture and manufacturing scale to address more price-sensitive hospitals and ambulatory surgery centers.
The surgical robotics market is expanding faster than the broader medical-device market. One market estimate places global surgical robotics revenue at $14.1 billion in 2025 and $45.6 billion in 2033, a 14.9% compound annual growth rate. Instruments and accessories represented 60.0% of that market estimate in 2025, closely matching ISRG's recurring-revenue-heavy structure.
The broader global medical-device market was estimated at $681.57 billion in 2025, with a projected 6.99% compound annual growth rate through 2030. ISRG's Q2 procedure growth of 16% and 2026 da Vinci guidance of 13.5% to 15.5% therefore show growth well above the broad device-market rate.
Market expansion depends on hospitals proving clinical and economic value. Gartner identifies operating-margin improvement, patient experience, and clinical workforce productivity as provider priorities, while Deloitte reports that 46% of healthcare executives identified affordability as a top 2025 trend. ISRG's lower-cost XiR systems, extended-use instruments, and digital workflow tools directly address those purchasing criteria.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
ISRG sells to hospitals, health systems, ambulatory surgery centers, surgeons, and diagnostic programs. The United States remains the largest installed-base market with 6,615 da Vinci systems as of June 30, 2026. Q2 U.S. placements reached 267, up 24% from 216 a year earlier, while 27 systems were placed at ASCs.
The ASC channel is becoming more important for cost-sensitive procedures. Twenty of the 27 Q2 ASC placements were XiR systems, showing a clear match between the lower-cost fourth-generation configuration and the economics of outpatient care. Refurbished Xi and X systems also attracted customers seeking access to the Gen 4 ecosystem at lower capital cost.
International customers supplied the faster procedure growth in Q2. Outside the United States, da Vinci procedures rose 20%, with Europe and Asia each growing 20% and rest-of-world markets increasing 22%. Japan placed 25 systems versus 15 a year earlier, while India delivered strong procedure momentum and received da Vinci 5 clearance during the quarter.
Customer retention also benefits from digital integration. The first wave of My Intuitive Plus renewals produced no opt-outs among the initial renewal cohort. The offering combines da Vinci 5 telepresence, simulation, and AI-driven case insights, adding software and workflow connectivity to the hardware relationship.
ISRG competes with Johnson & Johnson (JNJ), Medtronic (MDT), CMR Surgical, Distalmotion, Medicaroid, MicroPort MedBot, SS Innovations, Beijing Surgerii, Karl Storz, Noah Medical, and other robotic and non-robotic alternatives. The competitive field covers robotic platforms, laparoscopy, open surgery, stapling, energy devices, digital surgery, and diagnostic alternatives.
ISRG's advantage is ecosystem depth rather than a single machine specification. The company had 11,710 da Vinci systems installed worldwide by June 30, 2026, placed 468 da Vinci systems in one quarter, and supports surgeons through training, service, simulation, and clinical evidence. That installed base creates switching costs because hospitals build staffing, scheduling, and procedural expertise around the platform.
China is the clearest competitive pressure point. ISRG placed only two systems in China during Q2, citing lower tender activity, domestic robotic competition, and policy-driven pricing pressure. Da Vinci 5 remains outside Mainland China clearance, while MicroPort MedBot and other domestic suppliers compete in a market shaped by local procurement and pricing rules.
The competitive risk is real, but Q2 placement data still showed broad demand. ISRG placed 201 systems outside the United States, including 75 in Asia, 79 in Europe, and 47 in rest-of-world markets. Distributor markets produced 71 placements, up from 65 a year earlier, even as competitors targeted those markets.
U.S. procedure timing became a modest headwind in Q2. U.S. da Vinci procedure growth moderated to 12% from 14% in Q1, and management linked part of the moderation in deferrable procedures to the expiration of enhanced ACA premium subsidies. U.S. after-hours procedures still increased 26%, showing that demand remained broad even as some elective timing shifted.
Japan supplied a constructive policy signal. New policies effective June 1 included reimbursement for additional robotic procedures and economic incentives for higher-utilization programs. Japan's Q2 system placements increased to 25 from 15 a year earlier, connecting the policy change with a measurable capital response.
China remains exposed to tenders, provincial charge codes, quotas, and domestic competition. Management also cited shifting governmental priorities in parts of Europe and capital pressure tied to macroeconomic conditions. These factors matter because robotic systems require substantial hospital capital budgets before recurring procedure revenue begins.
Currency and tariff exposure add financial volatility. The 2025 10-K states that a 10% strengthening of the U.S. dollar against foreign currencies would have reduced revenue by approximately $140 million before considering the broader operating response. The same filing estimates that a 25-basis-point move in interest rates would change the fair value of the net investment position by approximately $19 million.
ISRG generated $3.03 billion of operating cash flow in 2025 and $2.49 billion of free cash flow, underscoring a balance sheet profile built on substantial internal cash generation.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue rose 19% to $2.89 billion while GAAP EPS reached $2.29, with recurring revenue contributing $2.47 billion or 85% of quarterly sales.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Analysts see revenue climbing to $13.27 billion and EPS to $12.08 in 2027, then reaching $18.49 billion of revenue and $17.00 of EPS by 2030.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →ISRG trades at 43.0x trailing earnings and 36.9x forward earnings, while its 2.7% free cash flow yield leaves the valuation case more restrained than the growth story.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework centers on a $475 fair value, with upside and downside bands stretching from $380 to $570 around the current Hold view.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →ISRG has the characteristics of a durable compounder: a 12,000-system-scale installed base, 85% recurring quarterly revenue, a 28.4% 2025 net margin, $2.49 billion of annual free cash flow, and net cash measured in billions rather than debt. Q2 2026 added evidence through 19% revenue growth, 16% procedure growth, and 246 da Vinci 5 placements.
The investment decision turns on price discipline. ISRG's $475.00 target recognizes the moat and the analyst-estimate trajectory through 2030, while the Hold rating reflects a rich starting multiple, slower 2026 procedure guidance, China headwinds, and a $401.27 quoted share price already carrying substantial optimism. The business merits a place on a medium-term quality list, but the strongest risk-adjusted entries sit below the current quote.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Intuitive Surgical, Inc. (ISRG) drops after investors reassess its post-earnings growth outlook. Despite strong Q2 results, slower procedure growth, tariff pressure, and a premium valuation are weighing on the stock.
Intuitive Surgical just got hit like the growth story broke, yet the quarter said the opposite. Revenue rose 19%, procedures stayed double-digit, and da Vinci 5 placements kept climbing, which makes this look more like an expectations reset than a business problem.
Intuitive Surgical, Inc. (ISRG) falls sharply after its Q2 2026 earnings report, even with an EPS beat. Investors focused on slower U.S. procedure growth and an unchanged outlook, triggering analyst target cuts and a valuation reset.